Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
about
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Clinical baseline factors predict response to natalizumab: their usefulness in patient selectionLong-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Epithelial V-like antigen mediates efficacy of anti-alpha₄ integrin treatment in a mouse model of multiple sclerosisHematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].
P2860
Q33573208-CC5C6095-A704-43D4-8514-2C5EE6FAABF0Q33712682-FC959746-1AA6-4E61-8E70-E57D97AF8D53Q33825885-7CD2F277-5E27-4E47-BF8D-B7E48927874BQ34948175-1635205F-CF12-45DE-B027-7CD05E824328Q35400555-A8D55C57-EFB0-4C60-8C04-04F8DB3365F2Q35684256-E0D9B25B-13CD-4E0A-8E7C-BD2D62923C11Q35998171-AD75AFD8-2F1D-455E-9257-4B0BF9A48974Q36669122-11A5C744-3CBC-4EEC-8936-82CC38F2A55BQ36789883-381F98E7-8020-4A54-8DA7-A9A71062F706Q37599583-565BB9AD-1747-45F1-A30B-3148BCE8F085Q39732691-D06C442C-AD15-4427-A3DE-E612843C564BQ40092065-DAE1D20E-DAA2-46AF-B32C-2BD57667E9A8Q42288520-82542869-B8D0-470C-A59A-7F8F8F820F61Q46406749-F40988E4-1CA7-4F48-9FA3-3B6D25E34540Q46835552-83F0F386-1E1D-4218-8403-CF02752F3595Q47639943-A36705FE-9977-43B1-BA65-F6D142E347E7Q47910873-C922C3C2-80AA-4D88-A57D-E2BD206F406DQ50956425-25A9EE37-B76F-4050-AF84-4D5FE3A89A0DQ52641471-0A75B02F-87FF-4FD0-8CF4-D33151062171Q53238466-2AD0BE57-7124-4373-9F02-C8A18455C38EQ53288359-B685BCB7-A0AA-4D7D-B79A-E9A2D8FA37E7
P2860
Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Predictors of freedom from dis ...... ients with multiple sclerosis.
@en
Predictors of freedom from dis ...... ients with multiple sclerosis.
@nl
type
label
Predictors of freedom from dis ...... ients with multiple sclerosis.
@en
Predictors of freedom from dis ...... ients with multiple sclerosis.
@nl
prefLabel
Predictors of freedom from dis ...... ients with multiple sclerosis.
@en
Predictors of freedom from dis ...... ients with multiple sclerosis.
@nl
P2093
P1476
Predictors of freedom from dis ...... tients with multiple sclerosis
@en
P2093
Carlo Pozzilli
Chiara Mancinelli
Federica Fubelli
Giovanna Borriello
Valeria Barletta
P304
P356
10.1016/J.JNS.2012.08.027
P577
2012-09-21T00:00:00Z